Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implicationsReportar como inadecuado

Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 13:271

Translational oncology


BackgroundCancer–testis antigens CTA comprise a family of proteins, which are physiologically expressed in adult human tissues solely in testicular germ cells and occasionally placenta. However, CTA expression has been reported in various malignancies. CTAs have been identified by their ability to elicit autologous cellular and or serological immune responses, and are considered potential targets for cancer immunotherapy. The breast differentiation antigen NY-BR-1, expressed specifically in normal and malignant breast tissue, has also immunogenic properties. Here we evaluated the expression patterns of CTAs and NY-BR-1 in breast cancer in correlation to clinico-pathological parameters in order to determine their possible impact as prognostic factors.

MethodsThe reactivity pattern of various mAbs 6C1, MA454, M3H67, 57B, E978, GAGE #26 and NY-BR-1 #5 were assessed by immunohistochemistry in a tissue micro array series of 210 randomly selected primary invasive breast cancers in order to study the diversity of different CTAs e.g. MAGE-A, NY-ESO-1, GAGE and NY-BR-1. These expression data were correlated to clinico-pathological parameters and outcome data including disease-free and overall survival.

ResultsExpression of at least one CTA was detectable in the cytoplasm of tumor cells in 37.2% of the cases. NY-BR-1 expression was found in 46.6% of tumors, respectively. Overall, CTA expression seemed to be linked to adverse prognosis and M3H67 immunoreactivity specifically was significantly correlated to shorter overall and disease-free survival p=0.000 and 0.024, respectively.

ConclusionsOur findings suggest that M3H67 immunoreactivity could serve as potential prognostic marker in primary breast cancer patients. The exclusive expression of CTAs in tumor tissues as well as the frequent expression of NY-BR-1 could define new targets for specific breast cancer therapies.

KeywordsBreast Cancer Cancer-testis Antigen NY-BR-1 Immunotherapy Prognosis Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-13-271 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Dimitrios Balafoutas - Axel zur Hausen - Sebastian Mayer - Marc Hirschfeld - Markus Jaeger - Dominik Denschlag - Gerald Git


Documentos relacionados